CHOP, Penn Medicine Develop CRISPR Platform for AML Drug Target Identification
Event summary
- Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania (Penn Medicine) have launched a CRISPR-based platform for identifying drivers of Acute Myeloid Leukemia (AML).
- The platform allows researchers to test potential cancer targets directly in patient cells, overcoming limitations of preclinical models and cell lines.
- The research, published in *Molecular Cell*, focuses on improving treatment options for AML, a cancer affecting approximately one in three adult leukemias.
- The platform achieved high gene-editing efficiency (86% for single-gene edits, 73% for high-throughput screening) and combined CRISPR with single-cell RNA sequencing for deeper insight.
The big picture
The development of this CRISPR-based platform represents a significant advancement in precision oncology, moving beyond preclinical models to directly analyze patient-derived cancer cells. This approach addresses a critical need in AML treatment, where resistance and relapse are common due to the genetic complexity of the disease. The ability to rapidly identify drug targets directly from patient samples could accelerate the development of more effective and personalized therapies, potentially disrupting the current treatment paradigm for AML.
What we're watching
- Clinical Translation
- The speed at which this research platform transitions from a research tool to a clinical diagnostic or treatment selection aid will depend on regulatory approvals and clinical trial success.
- Heterogeneity
- How effectively the platform can account for and leverage the heterogeneity of AML subtypes will be crucial for identifying truly personalized therapies and avoiding treatment resistance.
- Expansion
- The team's stated intention to apply the platform to other hard-to-treat leukemias suggests a potential expansion of the technology's scope, which could broaden its impact and revenue potential.
Related topics